Navigation Links
Intralytix, Inc. and BioPhage Therapeutics Limited Partner to Develop Topical Bacteriophage Treatments of Human Wounds Infected With S. Aureus
Date:4/5/2017

BALTIMORE, April 4, 2017 /PRNewswire/ -- Intralytix, Inc. announced today that the Company is partnering with BioPhage Therapeutics Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.

"Treatment of bacteria-infected wounds is one the most critical problems in modern medicine. Infected wounds complicate healing, often necessitate repeated surgical interventions, and may lead to amputation of extremities or even death.  The problem is compounded by the increasing emergence of multi-antibiotic-resistant bacteria – such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) - that may colonize the wounds and make their successful treatment very difficult or even impossible to achieve," stated Dr. Alexander Sulakvelidze, Intralytix's Chief Scientist.  "The ultimate goal of our partnership with BioPhage is to develop and make commercially available a novel phage-based topical treatment approach for managing wounds infected with S. aureus, including wounds infected with multidrug-resistant or pan-resistant strains (i.e., strains resistant to all major classes of antibiotics)," Dr. Sulakvelidze added.

"We view this partnership as an important step in developing phage-based products for managing wounds infected with S. aureus," stated John Woloszyn, Intralytix's CEO.  "Working with BioPhage Therapeutics, we aim to rapidly bring our bacteriophage technology to the market, and to offer a natural, safe, and effective antimicrobial approach to millions of people suffering from infected, hard-to-heal wounds," Mr. Woloszyn added.

Intralytix, Inc. is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, and dietary supplements and probiotics.  The Company has the world's largest portfolio of FDA-approved phage preparations for food safety applications and is involved in the development of several additional products for human therapeutic, veterinary medicine, probiotic, and other applications.

BioPhage Therapeutics Limited is a British company with strong skills in the clinical development, registration, and marketing of therapeutic drug products.  "The partnership with Intralytix is ideal," stated Robert Jackson, Chairman of BioPhage.  "We can build upon Intralytix's strength in bacteriophage science by formulating their phage into a drug product that will be in clinical trials at leading UK teaching hospitals by the end of the year."

For more information, contact: 

At Intralytix: Mr. John Woloszyn (410-625-3813 or jwoloszyn@intralytix.com) or Dr. Alexander Sulakvelidze (410-625-2533 or asulakvelidze@intralytix.com).

At BioPhage: Mr. Robert Jackson (+44-7785-318254 or robertwardjackson@msn.com) or Mr. Tim Butler (+44-7711-421944 or timbutler5@gmail.com).

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intralytix-inc-and-biophage-therapeutics-limited-partner-to-develop-topical-bacteriophage-treatments-of-human-wounds-infected-with-s-aureus-300434608.html


'/>"/>
SOURCE Intralytix, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Sorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial
2. Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma
3. Spiral Therapeutics Acquires an Exclusive Option to Develop Two Neuroprotective Agents for the Treatment of Inner Ear Disorders
4. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
5. Akcea Therapeutics Announces Three Additions to Board of Directors
6. Milner Therapeutics Institute Announces New Partnership with Elysium Health
7. ImMAGE Biotherapeutics DNA immunotherapy shows high efficacy with low toxicology results
8. Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center
9. Healthcare Stocks on Investors Radar -- Depomed, Novartis AG, TherapeuticsMD, and Tonix Pharma
10. Pain Therapeutics Attendee List Released Featuring Scientific Leaders and Top Industry Experts
11. PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 12, 2019 , ... Understanding the Drug ... FDAnews Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , ... Is the company clear on nuances of the guidelines regulating the drug supply ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... many companies developing technologies to evaluate medical images. In fact, image analysis software ... approaches the FDA is taking to AI-based image analysis, one will be left ...
(Date:9/11/2019)... (PRWEB) , ... September 11, 2019 , ... ... exposure to attempts by professionals to change a person’s gender identity from transgender ... suicide attempts. The study was authored by researchers at The Fenway Institute, Massachusetts ...
Breaking Medicine Technology:
(Date:9/11/2019)... , ... September 11, 2019 , ... ... be held September 11-14 in Minneapolis at the Mall of America Radisson Blu. ... will be faculty members for the high-profile, knee-focused conference, which brings together more ...
(Date:9/11/2019)... ... ... Ahipoki is excited to announce a new vegan and gluten free alternative ... and poke bowl fans alike. Ahimi is made of five simple ingredients including ... to tuna, Ahipoki customers will now have a vegan option when building ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... the ever-changing corporate landscape, Mediaplanet today announces the launch of its September, ... ranging from the importance of candid one-on-one conversations, ideas for improving wellness ...
(Date:9/9/2019)... ... 09, 2019 , ... Sharon, the respected Practice Administrator of ... Dental Office Management (AADOM) Annual Conference. This year, esteemed dentist, Dr. Patrick Cieplak, ... Sharon’s third nomination in a row. The entire team at Cieplak Dental Excellence ...
(Date:9/8/2019)... ... September 09, 2019 , ... Stetson University ... Best Regional Universities – South, released today. In addition, Stetson appears on five additional ... 11; Most Innovative Universities, No. 14; Campus Ethnic Diversity, No. 34; and a new ...
Breaking Medicine News(10 mins):